CHRS Stock Recent News

– Transaction aligns with Coherus' strategic focus on oncology – – Transaction aligns with Coherus' strategic focus on oncology –

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until July 7, 2024.

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Denny Lanfear - Chief Executive Officer Paul Reider - Chief Commercial Officer Rosh Dias - Chief Medical Officer Theresa LaVallee - Chief Development Officer Bryan McMichael - Interim Chief Financial Officer Conference Call Participants Michael Nedelcovych - TD Cowen Douglas Tsao - H.C. Wainwright Colleen Kusy - Baird Operator Ladies and gentlemen, thank you for standing by.

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.75 per share a year ago.

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%. Numbers on market share point to a strong Q1'24 for Udenyca, which could increase the market's confidence that CHRS can offset lost revenues from the Cimerli sale.

The biotech unveiled its latest set of quarterly and annual results. Its revenue for the former period rose sharply, but missed analyst expectations -- as did its bottom-line result.

Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript

Following the closing of its recently announced divestiture of its noncore ophthalmology business, Coherus will prepay a huge chunk of its term loan with Pharmakon. The move will reduce interest expenses by 70%, allowing Coherus to hone its focus on its oncology products.